Sobi's Pioneering Research at EULAR 2025
Sobi® (STO: SOBI) is gearing up to share innovative clinical findings at the renowned annual European Congress of Rheumatology, EULAR 2025. This major event will take place in Barcelona from June 11 to June 14. Attendees can expect to learn about cutting-edge clinical trial results focusing on the properties of Gamifant in treating macrophage activation syndrome, alongside updates from trials of Vonjo and its impact on VEXAS syndrome. An additional focus will be given to approaches for managing uncontrolled gout.
A Look at the Symposium
During the congress, Sobi is set to host a vital symposium aimed at exploring the diverse dermatologic, rheumatologic, and hematologic aspects of VEXAS syndrome. This session will be led by Dr. Sophie Georgin-Lavialle MD, PhD, a noted figure from the French National Reference Centre for auto-inflammatory diseases. Following the presentations, there will be an engaging panel discussion complemented by an interactive Q&A session.
Insights from Leadership
Lydia Abad-Franch, MD, MBA, who is the Head of Research, Development, and Medical Affairs at Sobi, expressed her enthusiasm: "We are thrilled to showcase our ongoing efforts in advancing treatment options for rare conditions at this year's EULAR conference. The information presented will provide valuable insights for professionals working with patients dealing with complex rheumatological ailments. We aim to equip them with the latest research data and treatment strategies." Abad-Franch added that this event highlights how collaborative research can lead to advancements in clinical practices.
Key Data Highlights
Some major topics that Sobi will present include:
- Gamifant (emapalumab):
- Efficacy and safety in patients with macrophage activation syndrome, through pooled analyses from two prospective trials. This session will feature Professor Fabrizio De Benedetti, who is a principal investigator of the study.
- Oral Presentation: This will occur in the Clinical Abstract Session focusing on Juvenile Idiopathic Arthritis, scheduled for Thursday, June 12, from 10:30 to 12:00 CEST.
- NASP (formerly SEL-212):
- Analysis of uncontrolled gout in patient populations ranging between rheumatologists and nephrologists through a poster session on Friday, June 13, from 10:15 to 11:45 CEST.
- Vonjo (pacritinib):
- Exploring development of a consensus definition of VEXAS flare via a poster presentation on Friday, June 13, 14:45 to 15:45 CEST.
Notable Presentations
Sobi will present results from the pivotal PAXIS study, assessing the safety and efficacy of pacritinib, concluding with valuable insights aimed at advancing VEXAS treatment. The presentation aims to engage the community by illuminating the significant role of ongoing research.
Exploring Product Offerings
Gamifant Overview
Gamifant (emapalumab) is aimed at treating both adults and children suffering from hemophagocytic lymphohistiocytosis (HLH), particularly for those who exhibit difficulty responding to standard therapies.
Understanding Macrophage Activation Syndrome (MAS)
MAS poses serious health risks as a complication of Still's disease, often leading to challenging systemic inflammation. With promising results from phase 2 trials, Gamifant shows potential in combating MAS effectively.
NASP's Role in Gout Management
Designed to manage high urate levels in those with uncontrolled gout, NASP represents a significant step forward in preventing the debilitating effects associated with this condition.
Vonjo and Its Applications
Approved for treatment in cases of primary and secondary myelofibrosis, Vonjo (pacritinib) focuses on patients with severe thrombocytopenia, demonstrating significant efficacy in reducing symptoms.
About Sobi
Sobi is a global biopharmaceutical company dedicated to enhancing the lives of those facing rare diseases. With a workforce of approximately 1,900 employees across various regions worldwide, Sobi's reach extends through Europe, North America, and beyond. In the previous year, Sobi achieved remarkable financial results with approximately SEK 26 billion in revenue. The company’s stock (STO: SOBI) is publicly traded on Nasdaq Stockholm, and ongoing updates on Sobi's operations can be found on their official website and social media platforms.
Frequently Asked Questions
What is the purpose of Sobi's participation at EULAR 2025?
Sobi aims to present their latest clinical data and research findings related to the treatment of rare diseases, particularly in the fields of rheumatology and related conditions.
What topics will Sobi present at the EULAR conference?
Sobi will present findings on Gamifant, NASP, and Vonjo, including updates on clinical trials and data regarding macrophage activation syndrome and uncontrolled gout.
Who will lead the symposium on VEXAS syndrome?
The symposium will be chaired by Dr. Sophie Georgin-Lavialle, who has extensive expertise in auto-inflammatory diseases.
How does Gamifant function for HLH patients?
Gamifant acts as an anti-IFN? antibody, addressing treatment challenges for patients experiencing hemophagocytic lymphohistiocytosis who do not respond well to conventional therapies.
What is Sobi's mission in the pharmaceutical industry?
Sobi is committed to unlocking new therapies that improve treatment modalities for rare diseases, ultimately transforming patients' quality of life through innovative solutions.
